Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mega Genomics Limited ( (HK:6667) ) is now available.
Mega Genomics Limited has issued a profit warning for the year ended 31 December 2025, flagging a strong rise in revenue to an estimated RMB240 million to RMB250 million from RMB164.2 million a year earlier. Despite this top-line growth, profit attributable to owners is expected to fall to about RMB25 million to RMB28 million, down sharply from roughly RMB45 million in 2024, as higher credit impairment losses and expenses related to the resumption of trading weigh on earnings.
The preliminary figures, based on unaudited management accounts that may still be adjusted, underline a year in which the company prioritized product expansion and portfolio diversification at the expense of margin pressure. Mega Genomics plans to release its full 2025 annual results on 31 March 2026, and has advised shareholders and potential investors to exercise caution when dealing in its shares amid the anticipated profit decline.
More about Mega Genomics Limited
Mega Genomics Limited is a Cayman Islands-incorporated company listed in Hong Kong that operates in the genomics and genetic testing sector. The group focuses on a diversified portfolio of genetic products and services, aiming to expand its product range and optimize its product mix to drive revenue growth in its target markets.
Average Trading Volume: 10,066
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.55B
See more data about 6667 stock on TipRanks’ Stock Analysis page.